Intervention

Trastuzumab Injection

ClinicalTrials.gov intervention label

How to interpret these research links

Connected source records

This is the original ClinicalTrials.gov intervention label, found in 4 distinct published trials. Registry interventions may represent drugs, devices, procedures or other study activities. A matched term or study association does not establish product equivalence, efficacy or regulatory approval.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Clinical trials4

Recruiting1

Common conditions6

Lead sponsors shown4

Clinical trials

4 shown

Capecitabine, Tucatinib, and Intrathecal Trastuzumab for Breast Cancer Patients With Leptomeningeal DiseaseNCT05800275 · 2023-12-18

RECRUITING

A Trial of SHR-A1811 Compared to Other Antitumor Therapies as Neoadjuvant Treatments in Early-stage or Locally Advanced HER2-positive Breast CancerNCT07196774 · 2025-10-23

ACTIVE_NOT_RECRUITING

Phase III to Evaluate Patient´s Preference of Subcutaneous Trastuzumab vs Intravenous in HER2+ Advanced Breast CancerNCT01875367 · 2013-09-18

COMPLETED

Clinical Trial of Comparative Study of GB221 PharmacokineticsNCT04175171 · 2011-11-07

COMPLETED

Common conditions

Breast Cancer1 Early-stage or Locally Advanced HER2-positive Breast Cancer1 HER2-positive Metastatic Breast Cancer1 Leptomeningeal Disease1 Leptomeningeal Metastasis1 Metastatic Breast Cancer1

Leading sponsors

Genor Biopharma Co., Ltd. 1 Jiangsu HengRui Medicine Co., Ltd. 1 Spanish Breast Cancer Research Group 1 UNICANCER 1

Trial status mix

COMPLETED2

ACTIVE_NOT_RECRUITING1

RECRUITING1

Phase mix

PHASE32

PHASE11

PHASE21

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.